Nuvectis Pharma, Inc.
NASDAQ:NVCTBiotechnology
Healthcare
$19.84 +3.06%
+$0.39 today
- Market cap
- $682.28M
- Beta
- -0.07
- P/E (TTM)
- -11.2
- EPS (TTM)
- -$1.16
52W Low $5.55High $13.51
Volume 0.16M
Average 0.08M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$27.57M
FY 2025 · Annual
Net Income
-$26.44M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 9.55M | 13.23M | 15.38M | 12.92M | 18.15M |
| Selling, General & Admin | 3.35M | 6.01M | 7.52M | 6.93M | 9.42M |
| Operating Expenses | 12.89M | 19.23M | 22.9M | 19.85M | 27.57M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| EBITDA | (12.89M) | (19.09M) | (22.26M) | (19M) | (26.44M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (12.89M) | (19.23M) | (22.9M) | (19.85M) | (27.57M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 4K | 149K | 637K | 847K | 1.13M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 4K | 149K | 637K | 847K | 1.13M |
| Income Before Tax | (12.89M) | (19.09M) | (22.26M) | (19M) | (26.44M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (12.89M) | (19.09M) | (22.26M) | (19M) | (26.44M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.09) | (1.51) | (1.43) | (1.11) | (1.32) |
| EPS (Diluted) | (1.09) | (1.51) | (1.43) | (1.11) | (1.32) |
| 12.72M | 12.66M | 15.56M | 17.11M | 21.81M | |
| 12.72M | 12.66M | 15.56M | 17.11M | 21.81M |
NVCT Earnings Waterfall · TTM
NASDAQ:NVCT · Revenue to Net Income
Key Ratios
EPS$-1.31
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-6.0
P/S Ratio0.0
Analysis
$0 of revenue converted into -$27.2M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.31, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 4, 2026 | |
| 10-Q | Quarterly report | Nov 4, 2026 | |
| EFFECT | EFFECT filing | Aug 28, 2026 | |
| S-3 | S-3 filing | Aug 21, 2026 | |
| 8-K | Current report | Aug 21, 2026 |
How much revenue does NVCT generate?
Nuvectis Pharma, Inc. (NVCT) reported $0.00 of revenue in fiscal 2025.
Is NVCT profitable?
Nuvectis Pharma, Inc. (NVCT) reported -$26.44M of net income.
Continue the stock analysis
Jump to another research area for this company.